Davidson Kempner Capital Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Davidson Kempner Capital Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-150,000	Closed	-$9K	–	476
2022 Q4	$9K	Hold	150,000	–	–	﹤0.01%	366
2022 Q3	$5K	Hold	150,000	–	–	﹤0.01%	507
2022 Q2	$6K	Hold	150,000	–	–	﹤0.01%	551
2022 Q1	$31K	Hold	150,000	–	–	﹤0.01%	559
2021 Q4	$90K	Hold	150,000	–	–	﹤0.01%	489
2021 Q3	$96K	Hold	150,000	–	–	﹤0.01%	436
2021 Q2	$129K	Buy	+150,000	New	+$104K	﹤0.01%	507

Davidson Kempner Capital Management's BIOTW Position: Q1 2023 in Review

Davidson Kempner Capital Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 150,000 shares — an estimated $9K sold.

Davidson Kempner Capital Management first reported a position in BIOTW in Q2 2021 and held it in 7 quarters. The position peaked at $129K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Davidson Kempner Capital Management reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Davidson Kempner Capital Management sold 150,000 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $9K.
Davidson Kempner Capital Management first reported a position in Biotech Acquisition Company Warrant in Q2 2021 and held it in 7 quarters.
Davidson Kempner Capital Management's Biotech Acquisition Company Warrant position peaked at $129K in Q2 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Davidson Kempner Capital Management's 13F filing for Q1 2023, filed 15 May 2023.